Oriol Mirallas MD· @DrMirallas · X·· 14 小时前评分70
正文 · 原文
🔥 Presidential Symposium I #ESMO26
🗣️ @sands_jacob @DanaFarber
DeLLphi-305 trial evaluating tarlatamab + durva vs durva as 1LM therapy for ES-SCLC.
✔️ mOS 21.1 vs 12.7m HR 0.42
✔️ mPFS 7.4 vs 1.9m HR 0.34
✔️ ORR 26.4 vs 4.1%
☣️ 46.8 vs 40.6% grade 3 or higher
@OncoAlert @myESMO @ASCO @_SEOM @UTMDAnderson @NEJM @brunolarvol
👇🏽👇🏽
151 浏览 · 6 赞 · 4 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Oriol Mirallas MD · x.com